GlucoTrack Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

GCTK$1.39-32.2%Stored close · as of Oct 29, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Changes in Stockholders’ Equity

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

	In thousands of US Dollars (except share data)
Common Stock · Receipts on · Accumulated
	Numbers of Shares	Amount	Additional Paid-in Capital	account of shares	Other Comprehensive Income	Accumulated Deficit	Total Stockholders’ Equity
Balance as of January 1, 2022	15,470,402	15	102,612	-	(6)	(97,466)	5,155
Loss for the year	-	-	-	-	-	(4,435)	(4,435)
Other comprehensive income	-	-	-	-	23	-	23
Stock-based compensation	13,105	-(*)-	439	-	-	-	439
Issuance of restricted shares as compensation towards directors	17,223	-(*)-	44	4	-	-	48
Balance as of December 31, 2022	15,500,730	15	103,095	4	17	(101,901)	1,230
Balance as of January 1, 2023	15,500,730	15	103,095	4	17	(101,901)	1,230
Loss for the year	-	-	-	-	-	(7,097)	(7,097)
Other comprehensive loss	-	-	-	-	(1)	-	(1)
Net proceeds received from underwritten U.S. public offering	5,376,472	5	8,725	-	-	-	8,730
Deemed dividend resulted from trigger of down round protection feature of certain warrants granted	-	-	855	-	-	(855)	-
Stock-based compensation	-	-	281	-	-	-	281
Issuance of restricted shares as compensation towards directors	14,991	-(*)	10	44	-	-	54
Balance as of December 31, 2023	20,892,193	20	112,966	48	16	(109,853)	3,197

(*)	Less than 1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.